[ad_1]
Herzliya, Israel and Calgary, Alberta, February 20, 2024 /CNW/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”) is a Iris Vinkovic I will be speaking at the White Label World Expo London upon February 27thth and 28th. She will speak on “The Magic of Proven Science in CBD Products” with top speakers from Alibaba, Google, LinkedIn, TikTok, and other sourcing experts, retail forecasting experts, and industry-defining leaders. , shares his thoughts on the hottest products of 2024. seller.
White Label World Expo is the world’s largest event for the white label industry, where sellers, suppliers and buyers gather to network, learn and explore opportunities. https://www.whitelabelexpo.co.uk/speakers/
Innocan’s consumer wellness portfolio features topical and cosmetic products backed by proven efficacy and patent applications, demonstrating our dedication to health and wellness and providing effective wellness products. We provide solutions to the growing consumer demand for.
Innocan’s participation in White Label World Expo is a joint venture, online marketplace, brick-and-mortar distribution, and white label partnership for the company to leverage its existing wellness brand consumer base and maximize market reach. supports diverse market access strategies.
About Innocan
Innocan is a pharmaceutical technology company that operates in two main segments: Pharmaceuticals and Consumer Wellness. In the pharmaceutical sector, Innocan focuses on developing innovative drug delivery platform technologies, including cannabinoid science, to treat a variety of conditions and improve patients’ quality of life. This segment includes his two drug delivery technologies. (i) LPT CBD-loaded liposome platform facilitates precise dosing and sustained and controlled release of CBD into the bloodstream. Research on the LPT delivery platform is in preclinical testing for two of his indications: epilepsy and pain management. In the Consumer Wellness segment, Innocan develops and markets a broad portfolio of innovative, high-performance self-care products to promote healthier lifestyles. Under this division, Innocan established a joint venture company named BI Sky Global Ltd, focused on developing highly targeted online sales. https://innocanpharma.com/
For more information, please contact us below.
For Innocan Pharma Corporation:
Iris Vinkovic, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
Neither the Canadian Securities Exchange nor its regulatory services provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Caution regarding information regarding future forecasts
Certain information contained in this news release includes, but is not limited to, the continued expansion of our wellness and cosmetic applications in the topical field, and our future prospects within the meaning of applicable securities laws. Information regarding the outlook. By its nature, forward-looking information involves a number of risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain important expectations and assumptions made by Innocan. This includes expectations and assumptions regarding the anticipated benefits of the products, the satisfaction of regulatory requirements in various jurisdictions, and the satisfactory completion of necessary production and sales arrangements. .
Forward-looking information is subject to various risks and uncertainties that could cause actual results or experience to differ materially from the anticipated results or expectations expressed in this news release. Principal risks and uncertainties include, but are not limited to: Governmental and Regulatory Requirements and Actions by Governmental Authorities. relationships with suppliers, manufacturers, customers, business partners and competitors; and specific to the nature of product distribution, including import and export issues, the inability to obtain (or timely) necessary regulatory and other approvals, and the availability of input and finished products in their respective markets. There is also a risk. product. Our anticipated schedule for market entry is subject to change for a variety of reasons, including our inability to secure necessary regulatory requirements and the need for additional time to enter into and/or satisfy manufacturing and distribution arrangements. . For the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release regarding the timing of product distribution. A comprehensive discussion of other risks affecting Innocan is also included in his Innocan public reports and filings available from his Innocan profile at www.sedarplus.ca.
Readers are cautioned not to place undue reliance on forward-looking information, as actual results may differ materially from such forward-looking information. Innocan does not undertake to update, amend or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law.
Photo – https://mma.prnewswire.com/media/2342559/Iris_Bincovich_White_Label_Expo.jpg
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content to download multimedia: https://www.prnewswire.com/news-releases/innocan-pharma-to-participate-in-the-white-label-world-expo- on-february-27-28th-2024 -302064991.html
SOURCE Innocan Pharma Corporation
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/20/c2419.html
[ad_2]
Source link
